Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long‐term follow‐up results
Open Access
- 7 August 2008
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 81 (3), 165-169
- https://doi.org/10.1111/j.1600-0609.2008.01100.x
Abstract
Objective: To evaluate the long-term activity and toxicity profile of rituximab in adult patients with idiopathic immune thrombocytopenic purpura (ITP). Patients and methods: Twenty-six patients with active and symptomatic ITP relapsed or refractory received weekly infusions of rituximab 375 mg/m2 for 4 wk. Median time from diagnosis to rituximab was 34.5 months. The following parameters of efficacy and toxicity were considered: complete response (CR) and partial response (PR), relapse rate, relapse-free survival (RFS), therapy-free survival (TFS), short- and long-term toxicity. Results: CR and PR were 14/26 (54%) and 4/26 (15%), respectively. Median time of observation was 56.5 months (range 39–77). Nine of the 18 responding patients relapsed after a median of 21 months (range 8–66); 9/26 patients (35%) maintained the response, with a median follow-up of 57 months (range 39–69), and 11/26 (42%) did not necessitate further therapy; estimated 5 yr RFS and TFS were 61% and 72%, respectively. Younger age and shorter interval from diagnosis to rituximab appeared indicators of better outcome. Rituximab administration was associated with two episodes of short-term toxicity, with one case of serum sickness syndrome; no infectious or other significant long-term complications were documented. Conclusion: Rituximab therapy may achieve long-lasting remission in nearly one-third of patients with relapsed or refractory ITP, with a good safety profile.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialThe Lancet, 2008
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- A Prospective Randomized Study of Rituximab and Dexamethasone vs Dexamethasone Alone in ITP.Blood, 2007
- Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?Current Opinion in Hematology, 2007
- Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic PurpuraAnnals of Internal Medicine, 2007
- Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.Blood, 2006
- Rituximab Is an Alternative to Splenectomy in Adults with Chronic Immune Thrombocytopenic Purpura: Results of a Multicenter Prospective Phase 2 Study.Blood, 2006
- Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopeniaExperimental Hematology, 2006
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]Blood, 1996